PARP1 and myeloproliferative neoplasm: This agent inhibits class I HDACs.2 FK228 induced proteolysis-dependent activation of the ultimate apoptosis executioner enzyme caspase-3 and cleavage of its substrate PARP1 in all three MPN cell systems (Fig. 1a and Supplementary Fig. 1a–c).